ARTICLE | Company News
Ocugen, University of Colorado deal
June 16, 2014 7:00 AM UTC
The university granted Ocugen exclusive, worldwide rights to assets related to PC4 and SFRS1-interacting protein ( PSIP1; LEDGF; p75; LEDGF/p75), including preclinical compounds OCU100 and OCU200...